Horizon Therapeutics USA, Inc
Registered Principal Details
Cessation Date
1/19/2024 1:35:27 PM
Business Or Interest:
Pharmaceutical industry and medicines for rare, autoimmune and severe inflammatory diseases.
Lobbying Interests:
All matters relating to the pharmaceutical industry and medicines for rare, autoimmune and severe inflammatory diseases
CEO Name:
Tim Walbert
1/19/2024 1:35:27 PM
Business Or Interest:
Pharmaceutical industry and medicines for rare, autoimmune and severe inflammatory diseases.
Lobbying Interests:
All matters relating to the pharmaceutical industry and medicines for rare, autoimmune and severe inflammatory diseases
CEO Name:
Tim Walbert
Contact
JI
Julie Idelkope
1 Horizon Way
Deerfield, IL 60015
(612) 805-5493
jidelkope@horizontherapeutics.com
https://www.horizontherapeutics.com/
1 Horizon Way
Deerfield, IL 60015
(612) 805-5493
jidelkope@horizontherapeutics.com
https://www.horizontherapeutics.com/
Authorized Lobbyists
| Lobbyist Name | Exclusive Duties | Authorized On | Withdrawn On |
|---|
Lobbying Interests
Legislative Bills/Resolutions
Senate Bill 100
Relating to: application of prescription drug payments to health insurance cost-sharing requirements.
Bill Text and History
3/10/2023
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Relating to: application of prescription drug payments to health insurance cost-sharing requirements.
Bill Text and History
For
Notification Date3/10/2023
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Topics Not Yet Assigned A Bill Or Rule Number
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal related to rare diseases.
Development, drafting or introduction of a proposal related to rare diseases.
Action Intended To Affect
Both Legislative matter and rule
Notification Date
1/30/2023
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Both Legislative matter and rule
Notification Date
1/30/2023
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Development, drafting or introduction of a proposal relating to regulation of pharmaceutical manufacturers.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal relating to regulation of pharmaceutical manufacturers.
Development, drafting or introduction of a proposal relating to regulation of pharmaceutical manufacturers.
Action Intended To Affect
Both Legislative matter and rule
Notification Date
1/30/2023
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Both Legislative matter and rule
Notification Date
1/30/2023
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Development, drafting or introduction of a proposal relating to the application of prescription drug payments for health coverage.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal relating to the application of prescription drug payments for health coverage.
Development, drafting or introduction of a proposal relating to the application of prescription drug payments for health coverage.
Action Intended To Affect
Both Legislative matter and rule
Notification Date
1/30/2023
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Both Legislative matter and rule
Notification Date
1/30/2023
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Development, drafting or introduction of a proposal relating to the creation of a Rare Disease Advisory Council.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal relating to the creation of a Rare Disease Advisory Council.
Development, drafting or introduction of a proposal relating to the creation of a Rare Disease Advisory Council.
Action Intended To Affect
Both Legislative matter and rule
Notification Date
12/19/2022
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
12/19/2022
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Total Lobbying Effort
| 2023 January - June |
2023 July - December |
2024 January - June |
Total | |
|---|---|---|---|---|
| Total Lobbying Expenditures | 2023 January - June $30,420.00 |
2023 July - December $18,000.00 |
2024 January - June $0.00 |
Total $48,420.00 |
| Total Hours Communicating | 2023 January - June 0.00 |
2023 July - December 0.00 |
2024 January - June 0.00 |
Total 0.00 |
| Total Hours Other | 2023 January - June 15.50 |
2023 July - December 0.00 |
2024 January - June 0.00 |
Total 15.50 |
Percent Allocation of Lobbying Effort
Legislative Bills/Resolutions
Relating to: application of prescription drug payments to health insurance cost-sharing requirements.
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June 50% |
2023 July - December |
2024 January - June |
2024 July - December |
Total 52% |
Budget Bill Subjects
No budget bill subjects found.
Administrative Rulemaking Proceedings
No administrative rulemaking proceedings found.
Topics Not Yet Assigned A Bill Or Rule Number
Development, drafting or introduction of a proposal relating to the application of prescription drug payments for health coverage.
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June 10% |
2023 July - December |
2024 January - June |
2024 July - December |
Total 10% |
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June 20% |
2023 July - December |
2024 January - June |
2024 July - December |
Total 20% |
Development, drafting or introduction of a proposal relating to the creation of a Rare Disease Advisory Council.
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June 20% |
2023 July - December |
2024 January - June |
2024 July - December |
Total 20% |
Minor Efforts
No minor efforts found.
Other Matters
Includes time spent on:
- Gubernatorial nominations
- Matters on which the organization made no lobbying communication